Treatment Clinical Trials for Multiple Myeloma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for multiple myeloma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 211
1 2 3 ... 9 Next >

  • NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1169 locations

  • Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma

    This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma
    Location: 815 locations

  • Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma

    This randomized phase III trial studies standard-dose lenalidomide, bortezomib, and dexamethasone (RVD) to see how well it works compared to high-dose RVD followed by peripheral blood stem cell transplant (PBSCT) in treating patients with multiple myeloma (MM). Giving RVD before a PBSCT may help stop the growth of cancer cells by stopping them from dividing, killing them, blocking the enzymes needed for cell growth, or stimulating the immune system. After treatment, stem cells are collected from the patient’s blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by RVD combination therapy. It is not yet known whether standard-dose RVD is more effective than high-dose RVD followed by PBSCT in treating MM.
    Location: 51 locations

  • Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

    The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.
    Location: 26 locations

  • Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

    This study is designed to compare long-term outcomes among patients randomized on the BMT CTN 0702 protocol (NCT01109004), "A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma". It is hypothesized that use of novel anti-myeloma agents will improve long-term progression-free survival (PFS) after high-dose melphalan followed by autologous hematopoietic cell transplantation (HCT) as compared to a second autologous transplantation.
    Location: 15 locations

  • Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

    This study is designed to compare progression-free survival (PFS) from randomization among patients randomized on the BMT CTN 1302 protocol, "Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma". It is hypothesized that Ixazomib maintenance therapy will result in improved PFS in patients with high-risk multiple myeloma following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) compared to placebo.
    Location: 14 locations

  • Selinexor Treatment of Refractory Myeloma

    This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
    Location: 17 locations

  • Ipilimumab or Nivolumab in Treating Patients with Relapsed Hematologic Malignancies after Donor Stem Cell Transplant

    This phase I / Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of improvement (relapsed) after donor stem cell transplant. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread.
    Location: 12 locations

  • Direct Oral Anticoagulants (DOACs) Versus LMWH + / - Warfarin for VTE in Cancer

    The overarching objective of the study is to determine the effectiveness of LMWH / warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.
    Location: 12 locations

  • Dendritic Cell / Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

    The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell / myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy versus maintenance therapy alone or with GM-CSF following autologous transplant as part of upfront treatment of multiple myeloma (MM). It is hypothesized that the dendritic cell myeloma vaccine will result in improved response in patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT).
    Location: 14 locations

  • Nivolumab, Lenalidomide, and Low Dose Dexamethasone in Treating Patients with High-Risk Smoldering Multiple Myeloma

    This phase II trial studies how well nivolumab, lenalidomide, and low dose dexamethasone work in treating patients with high-risk smoldering multiple myeloma. Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab, lenalidomide, and low dose dexamethasone may work better in treating patients with high-risk smoldering multiple myeloma.
    Location: 9 locations

  • Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)

    This is a non-randomized, open-label study evaluating the safety and efficacy of pembrolizumab (MK-3475) used in combination with dinaciclib (MK-7965) in the treatment of relapsed or refractory chronic lymphocytic leukemia (rrCLL), multiple myeloma (rrMM), or diffuse large B-cell lymphoma (rrDLBCL) in up to 138 participants from multiple sites. During an initial Dose Evaluation phase (first 2 cycles) to determine Dose Limiting Toxicities (DLTs), dose combinations of pembrolizumab 200 mg followed by dinaciclib 7 mg / m^2, pembrolizumab 200 mg followed by dinaciclib 10 mg / m^2, and pembrolizumab 200 mg followed by dinaciclib 14 mg / m^2 will be evaluated. Following safety review of the Dose Evaluation Phase, approximately 30 participants each will be enrolled in rrCLL, rrMM, or DLBCL cohorts during the Signal Detection phase. For each disease type objective response rate (ORR) will be determined by disease specific criteria.
    Location: 10 locations

  • Ixazomib, Lenalidomide, and Dexamethasone as Consolidation Therapy Followed by Maintenance Ixazomib or Lenalidomide after Stem Cell Transplant in Treating Patients with Multiple Myeloma

    This partially randomized phase II trial studies how well ixazomib, lenalidomide, and dexamethasone as consolidation therapy followed by maintenance ixazomib or lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Ixazomib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib with lenalidomide and dexamethasone as consolidation therapy may help prolong the amount of time patients are disease-free after a stem cell transplant. It is not yet known whether giving ixazomib, lenalidomide, and dexamethasone followed by maintenance ixazomib or lenalidomide works better in treating patients with multiple myeloma after a stem cell transplant.
    Location: 9 locations

  • Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of idasanutlin and ixazomib citrate when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement. Drugs used in chemotherapy, such as idasanutlin and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving idasanutlin, ixazomib citrate, and dexamethasone together may work better in treating patients with multiple myeloma.
    Location: 7 locations

  • Phase 1 / 2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

    Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD) / maximum administered dose (MAD) of SAR650984 (Isatuximab). Phase 2 (stage 1): To evaluate the activity of single-agent Isatuximab at different doses / schedules and to select dose and regimen to further evaluate the overall response rate (ORR) of Isatuximab as single agent or in combination with dexamethasone. Phase 2 (stage 2): To evaluate the activity in terms of overall response rate (ORR) of Isatuximab at the selected dose / schedule from stage1, as single agent (ISA arm) and in combination with dexamethasone (ISAdex arm). Secondary Objectives: Phase 1: - To characterize the global safety profile including cumulative toxicities. - To evaluate the pharmacokinetic (PK) profile of Isatuximab in the proposed dosing schedule(s). - To assess the pharmacodynamics (PD), immune response, and preliminary disease response. Phase 2 (stage 1): to evaluate the following objectives for Isatuximab as single agent: - Safety - Efficacy as measured by duration of response, clinical benefit rate, progression free survival, overall survival. Phase 2 (stage 2): to evaluate the following objectives in each arm (ISA and ISAdex): - Safety - Efficacy as measured by duration of response, clinical benefit rate, progression free survival, overall survival.
    Location: 12 locations

  • Study of bb2121 in Multiple Myeloma

    Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed / refractory multiple myeloma (MM).
    Location: 8 locations

  • A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

    Primary Objective: - Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed / refractory multiple myeloma (RRMM). - Part B: To evaluate the activity of SAR650984 (isatuximab) as assessed by overall response rate (ORR) in RRMM patients previously treated with daratumumab. Secondary Objectives: - Part A: - To determine the pharmacokinetics (PK) of SAR650984 (isatuximab) in patients with RRMM. - Part B: - To evaluate the safety of SAR650984 (isatuximab). - To evaluate the efficacy of SAR650984 (isatuximab) as assessed by duration of response (DOR), clinical benefit rate (CBR) and progression free survival (PFS). - To assess the pharmacokinetics (PK) of SAR650984 (isatuximab) and daratumumab at baseline. - To evaluate the immunogenicity of SAR650984 (isatuximab).
    Location: 7 locations

  • Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

    This is a Phase II, open-label, non-randomized, multi-center study of oral Dabrafenib in combination with oral Trametinib in subjects with rare cancers including anaplastic thyroid cancer, biliary tract cancer, gastrointestinal stromal tumor, non-seminomatous germ cell tumor / non-geminomatous germ cell tumor, hairy cell leukemia, World Health Organization (WHO) Grade 1 or 2 glioma, WHO Grade 3 or 4 (high-grade) glioma, multiple myeloma, and adenocarcinoma of the small intestine, with BRAF V600E positive-mutations. This study is designed to determine the overall response rate (ORR) of oral Dabrafenib in combination with oral Trametinib in subjects with rare BRAF V600E mutated cancers. Subjects will need to have a fresh or frozen tumor tissue sample provided to confirm the BRAF V600E mutation status. Only subjects with histologically confirmed advanced disease and no available standard treatment options will be eligible for enrollment. Subjects will undergo screening assessments within 14 days (up to 35 days for ophthalmology exam, echocardiogram or disease assessments) prior to the start of treatment to determine their eligibility for enrollment in the study.
    Location: 8 locations

  • Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients with Newly-Diagnosed Multiple Myeloma

    This phase II trial studies how well daratumumab, carfilzomib, lenalidomide, and dexamethasone work in treating patients with newly-diagnosed multiple myeloma. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab, carfilzomib, lenalidomide, and dexamethasone may work better in treating patients with multiple myeloma.
    Location: 6 locations

  • A Safety Study of SGN-CD352A for Patients With Relapsed / Refractory Multiple Myeloma

    This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.
    Location: 7 locations

  • Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients with Newly-Diagnosed Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of carfilzomib when given together with lenalidomide and dexamethasone and to see how well they work in treating patients with newly-diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib together with lenalidomide and dexamethasone may work better in treating patients with newly-diagnosed multiple myeloma.
    Location: 6 locations

  • Selinexor, Ixazomib Citrate, and Low Dose Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I trial studies the side effects and best dose of selinexor when given together with ixazomib citrate and low dose dexamethasone in treating patients with multiple myeloma that has come back or has not responded to treatment. Selinexor and ixazomib citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor, ixazomib citrate, and dexamethasone may work better in treating patients with multiple myeloma.
    Location: 6 locations

  • Elotuzumab, Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase II trial studies the side effects and how well elotuzumab, pomalidomide, bortezomib, and dexamethasone work in treating patients with multiple myeloma that has come back or does not respond to treatment. Monoclonal antibodies, such as elotuzumab, may interfere with the ability of cancer cells to grow and spread. Pomalidomide may enhance or suppress the reaction of the immune system to a stimulus which may help the body destroy cancer cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone may act against cancer cells and prevent inflammation in a wide variety of organs. Giving elotuzumab, pomalidomide, bortezomib, and dexamethasone may work better in treating patients with multiple myeloma.
    Location: 7 locations

  • Ixazomib Citrate and Dexamethasone in Treating Patients with High Risk Smoldering Multiple Myeloma

    This pilot phase I trial studies how well ixazomib citrate and dexamethasone work in treating patients with smoldering multiple myeloma that is likely to come back or spread (high-risk). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Corticosteroids, such as dexamethasone, affect the function of many cells within the body, suppress the immune system, block inflammation, and are used in a wide variety of inflammatory diseases affecting many organs. Giving ixazomib citrate with dexamethasone may work better in treating smoldering multiple myeloma.
    Location: 6 locations

  • SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

    A Phase 1 / 2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
    Location: 6 locations


1 2 3 ... 9 Next >